References
- Prescription Opioid Overdose Data [Internet]. Centers for Disease Control and Prevention. 2017. [accessed 2018 Jul 24]. https://www.cdc.gov/drugoverdose/data/overdose.html.
- Chen LH, Hedegaard H, Warner M. Drug-poisoning Deaths Involving Opioid Analgesics: United States, 1999-2011. Hyattsville, MD: National Center for Health Statistics; 2014 Sept. NCHS data brief, no. 166.
- Opioids and Substance Use [Internet]. Texas Health and Human Services. [accessed 2019 Dec 10]. http://healthdata.dshs.texas.gov/Substance/Deaths.
- Karacostas C. Scale of opioid epidemic in Texas likely obscured by bad data, experts say. The Daily Texan. 2017.
- Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015;16(8):769–80. doi:10.1016/j.jpain.2015.05.002.
- Naloxone hydrochloride [package insert]. Hospira, Inc., Lake Forest, IL; 2019.
- Bailey AM, Wermeling DP. Naloxone for Opioid Overdose Prevention: pharmacists' role in community-based practice settings. Ann Pharmacother. 2014;48(5):601–6. doi:10.1177/1060028014523730.
- Tewell R, Edgerton L, Kyle E. Establishment of a pharmacist-led service for patients at high risk for opioid overdose. Am J Health Syst Pharm. 2018;75(6):376–83. doi:10.2146/ajhp170294.
- Freise JE, Mccarthy EE, Guy M, Steiger S, Sheu L. Increasing naloxone co-prescription for patients on chronic opioids: a student-led initiative. J Gen Intern Med. 2018;33(6):797–8. doi:10.1007/s11606-018-4397-7.
- Coffin PO, Behar E, Rowe C, Santos G-M, Coffa D, Bald M, Vittinghoff E. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016;165(4):245–52.
- Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: An evaluation of six overdose training and naloxone distribution programs in the United States. Addiction. 2008;103(6):979–89.
- Devries J, Rafie S, Polston G. Implementing an overdose education and naloxone distribution program in a health system. J Am Pharm Assoc. 2017;57(2S):S154–S60. doi:10.1016/j.japh.2017.01.002.
- Zschoche JH, Nesbit S, Murtaza U, et al. Development and implementation of procedures for outpatient naloxone prescribing at a large academic medical center. Am J Heal Pharm. 2018;75:e631–40. doi:10.2146/ajhp170759.
- Behar E, Bagnulo R, Coffin PO. Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review. Prev Med. 2018;114(May):79–87. doi:10.1016/j.ypmed.2018.06.005.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA. 2016;315(15):1624–45. doi:10.1001/jama.2016.1464.
- Takeda MY, Katzman JG, Dole E, Bennett MH, Alchbli A, Duhigg D, Yonas H. Co-prescription of naloxone as a universal precautions model for patients on chronic opioid therapy-Observational study. Subst Abus. 2016;37(4):591–6. doi:10.1080/08897077.2016.1179704.
- Muir JC, Scheffey C, Young HM, Vilches AO, Davis MS, Connor SR. Opioid prescribing practices before and after initiation of palliative care in outpatients. J Pain Symptom Manage. 2013;45(6):1107–11. doi:10.1016/j.jpainsymman.2012.06.006.
- Percocet (R) [package insert]. Endo Pharmaceuticals Inc., Chadds Ford, PA; 2006.
- Wulz JL, Sung H, Dugan BDA, Wensel TM, Lander R, Manzella B. The pharmacist role in the development and implementation of a naloxone prescription program in Alabama. J Am Pharm Assoc (2003). 2017;57(2S):S141–7. doi:10.1016/j.japh.2016.12.078.
- Zedler B, Xie L, Wang L, Joyce A, Vick C, Kariburyo F, Rajan P, Baser O, Murrelle L. Risk factors for serious prescription opioid-related toxicity or overdose among veterans health administration patients. Pain Med. 2014;15(11):1911–29. doi:10.1111/pme.12480.
- Miller M, Barber CW, Leatherman S, Fonda J, Hermos JA, Cho K, Gagnon DR. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. 2015;175(4):608–15. doi:10.1001/jamainternmed.2014.8071.
- Lim JK, Bratberg JP, Davis CS, Green TC, Walley AY. Prescribe to prevent: overdose prevention and naloxone rescue kits for prescribers and pharmacists. J Addict Med. 2016;10(5):300–8. doi:10.1097/ADM.0000000000000223.
- Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case–control study. PLoS Med. 2017;14(10):e1002396.
- Garg RK, Fulton-Kehoe D, Franklin GM. Patterns of opioid use and risk of opioid overdose death among medicaid patients. Med Care. 2017;55(7):661–8. doi:10.1097/MLR.0000000000000738.
- Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58–64. doi:10.1016/j.drugalcdep.2017.01.013.
- NCCN Guidelines Panel. NCCN clinical practice guidelines in oncology: palliative care. National Comprehensive Cancer Network; 2018. Version 1.2018.